Welcome to our dedicated page for Rockwell Med SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rockwell Medical, Inc. (Nasdaq: RMTI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Rockwell Medical files current reports on Form 8-K and periodic reports such as Form 10-Q, which together offer detailed information on its financial condition, operating performance, corporate governance, and key business developments related to its hemodialysis products for dialysis providers worldwide.
Through Rockwell Medical’s Form 8-K filings, users can review disclosures about material events, including quarterly financial results, updated corporate presentations, and changes in the composition of the board of directors or executive leadership. For example, the company has used Form 8-K to announce financial results for specific quarters, to furnish investor presentations, and to report appointments and resignations of directors and senior officers, along with related compensation and equity awards.
Quarterly reports on Form 10-Q, referenced in Rockwell Medical’s announcements, contain more extensive financial statements and notes, as well as management’s discussion of net sales, gross profit, gross margin, operating income or loss, adjusted EBITDA, and cash position. These filings also provide context on customer contracts, such as the impact of large customers transitioning to other suppliers and the extent of long-term agreements with dialysis providers.
On Stock Titan, Rockwell Medical’s SEC filings are presented with real-time updates from the EDGAR system and AI-powered summaries that explain the key points in plain language. Users can quickly understand the implications of a new 8-K or 10-Q, see how financial metrics are trending, and identify disclosures about corporate governance or compensation arrangements. This page is a resource for investors and analysts who want to examine Rockwell Medical’s official regulatory history and interpret the company’s hemodialysis-focused business through its SEC reports.
Rockwell Medical, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 12, 2026. The agenda includes electing two Class II directors through 2029, an advisory vote on executive pay, ratifying EisnerAmper LLP as auditor, and approving a reverse stock split amendment.
Holders of 39,405,302 common shares as of April 16, 2026 can vote, with one vote per share. The proxy also details board structure, committee independence, executive employment terms, performance-based equity awards, severance and change-in-control protections, stock ownership guidelines, clawback policy, and anti-hedging and anti-pledging rules.
Rockwell Medical, Inc. has circulated a preliminary proxy statement for its 2026 Annual Meeting, to be held virtually on June 12, 2026. Items for shareholder vote include election of two Class II directors, an advisory vote on executive compensation, ratification of EisnerAmper LLP as auditor, and a proposal to amend the Certificate of Incorporation to effect a reverse stock split. Only holders of record on April 16, 2026 may vote. The Board recommends voting FOR all proposals. Proxy materials and the 2025 Annual Report are available at the virtual meeting website.
Neri Jesse reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. reported that its SVP, Finance and CFO, Jesse Neri, received a grant of 97,500 performance-based restricted stock units (PSUs) on May 20, 2025. Each PSU represents the right to receive one share of common stock.
The PSUs have a three-year term ending on May 20, 2028. Any units that remain unvested at that third anniversary will be cancelled. Vesting can occur on or after the first anniversary of the grant date, but only if a performance hurdle is met.
The performance hurdle is satisfied if the average closing price of Rockwell Medical’s common stock over any 60 consecutive trading days during the three-year performance period equals two times the base price. The base price for this award is $2.14 per share. Following this grant, Neri holds 97,500 PSUs directly.
TIMMINS MEGAN C. reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. executive Megan C. Timmins, EVP, CLO and Secretary, received a grant of 97,500 performance-based restricted stock units (PSUs) tied to the company’s common stock. This is a compensation-related award, not an open-market stock purchase or sale.
The PSUs run for three years from the grant date and any unvested units are cancelled after the third anniversary. They can vest on or after the first anniversary only if a share-price performance hurdle is met over a 60-day trading window, using a base price of $2.14.
Chole Timothy reported acquisition or exercise transactions in this Form 4 filing.
ROCKWELL MEDICAL, INC. reported that SVP and Chief Commercial Officer Timothy Chole received a grant of 85,000 performance-based restricted stock units on May 20, 2025. Each unit relates to one share of common stock and was awarded at no cash cost.
The PSUs have a three-year term ending on the third anniversary of the grant date, with an expiration date of May 20, 2028. They vest on or after the first anniversary only if a stock-price performance hurdle is achieved.
The performance hurdle is met if the average closing price of Rockwell Medical’s common stock over any 60 consecutive trading days during the three-year performance period equals two times the base price. The base price for this award is $2.14, calculated from the average closing price over the ten trading days before the grant.
Strobeck Mark reported acquisition or exercise transactions in this Form 4 filing.
Rockwell Medical, Inc. reported that President and CEO Mark Strobeck received a grant of 352,000 performance-based restricted stock units (PSUs) tied to the company’s common stock. The PSUs have a three-year term from the May 20, 2025 grant date and expire on May 20, 2028.
The units vest only if a stock price performance hurdle is achieved. During the three-year performance period, the average closing price over any 60 consecutive trading days must reach two times the base price. The base price for this award is $2.14, calculated from the average closing price over the ten trading days before the grant date.
Rockwell Medical, Inc. furnished an updated corporate presentation as part of a current report. The presentation, dated March 26, 2026, is attached as Exhibit 99.1 and provides corporate information under Regulation FD.
The company notes this material is furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced.
Rockwell Medical details its hemodialysis concentrates business, 2025 milestones, and mounting risks in its annual report. The company serves 294 customers, including all five leading U.S. dialysis providers, with dialysate concentrates making up 100% of 2025 revenue and about 88% of sales in the United States.
DaVita accounted for 16% of 2025 net product sales, down from 45% in 2024, after an attempted transition to another supplier. A second amendment extended Rockwell’s DaVita supply agreement through December 31, 2026 with higher pricing. Rockwell ended manufacturing at its South Carolina facility to streamline costs and added 30 new western U.S. customers.
At December 31, 2025, Rockwell reported about $25.0 million in cash, cash equivalents and available-for-sale investments, working capital of $28.6 million, and net cash used in operations of roughly $0.7 million for the year. Management believes capital is sufficient for at least 12 months but warns that additional funding, covenant compliance under its Innovatus term loan, customer concentration, cost inflation, and evolving kidney disease treatments could materially affect future results.
Rockwell Medical, Inc. reported fourth quarter and full-year 2025 results showing a sharp revenue decline but improved margins and positive cash generation. Net sales were $18.3 million in Q4 2025 versus $24.7 million a year earlier, and $69.3 million for 2025 compared with $101.5 million in 2024, mainly due to lower purchase volume from one customer.
Q4 2025 gross margin improved to 21% from 15%, with full-year 2025 gross margin steady at 17%. The company posted a 2025 net loss of $5.3 million versus $0.5 million in 2024, but remained profitable on an Adjusted EBITDA basis at $0.3 million. Cash, cash equivalents and investments were $25.0 million at December 31, 2025, up from $21.6 million. For 2026, Rockwell guides to Adjusted EBITDA of $1 million to $2 million and positive operating cash flow.